These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38377647)

  • 1. Impact of newborn screening for fatty acid oxidation disorders on neurological outcome: A Belgian retrospective and multicentric study.
    Everard E; Laeremans H; Boemer F; Marie S; Vincent MF; Dewulf JP; Debray FG; De Laet C; Nassogne MC
    Eur J Paediatr Neurol; 2024 Mar; 49():60-65. PubMed ID: 38377647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up of fatty acid β-oxidation disorders in expanded newborn screening era.
    Janeiro P; Jotta R; Ramos R; Florindo C; Ventura FV; Vilarinho L; Tavares de Almeida I; Gaspar A
    Eur J Pediatr; 2019 Mar; 178(3):387-394. PubMed ID: 30617651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Newborn Screening and Early Dietary Management on Clinical Outcome of Patients with Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency and Medium Chain Acyl-CoA Dehydrogenase Deficiency-A Retrospective Nationwide Study.
    Rücklová K; Hrubá E; Pavlíková M; Hanák P; Farolfi M; Chrastina P; Vlášková H; Kousal B; Smolka V; Foltenová H; Adam T; Friedecký D; Ješina P; Zeman J; Kožich V; Honzík T
    Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle MRI in patients with long-chain fatty acid oxidation disorders.
    Diekman EF; van der Pol WL; Nievelstein RA; Houten SM; Wijburg FA; Visser G
    J Inherit Metab Dis; 2014 May; 37(3):405-13. PubMed ID: 24305961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fasting, feeding and exercise on plasma acylcarnitines among subjects with CPT2D, VLCADD and LCHADD/TFPD.
    Elizondo G; Matern D; Vockley J; Harding CO; Gillingham MB
    Mol Genet Metab; 2020; 131(1-2):90-97. PubMed ID: 32928639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatal pitfalls in newborn screening for mitochondrial trifunctional protein (MTP)/long-chain 3-Hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency.
    Lotz-Havla AS; Röschinger W; Schiergens K; Singer K; Karall D; Konstantopoulou V; Wortmann SB; Maier EM
    Orphanet J Rare Dis; 2018 Jul; 13(1):122. PubMed ID: 30029694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians.
    Potter BK; Little J; Chakraborty P; Kronick JB; Evans J; Frei J; Sutherland SC; Wilson K; Wilson BJ
    J Inherit Metab Dis; 2012 Jan; 35(1):115-23. PubMed ID: 21630065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Metabolic Defects in Fatty Acid Oxidation Using Peripheral Blood Mononuclear Cells Loaded with Deuterium-Labeled Fatty Acids.
    Yuasa M; Hata I; Sugihara K; Isozaki Y; Ohshima Y; Hara K; Tajima G; Shigematsu Y
    Dis Markers; 2019; 2019():2984747. PubMed ID: 30881520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological outcome in long-chain hydroxy fatty acid oxidation disorders.
    Mütze U; Ottenberger A; Gleich F; Maier EM; Lindner M; Husain RA; Palm K; Beblo S; Freisinger P; Santer R; Thimm E; Vom Dahl S; Weinhold N; Grohmann-Held K; Haase C; Hennermann JB; Hörbe-Blindt A; Kamrath C; Marquardt I; Marquardt T; Behne R; Haas D; Spiekerkoetter U; Hoffmann GF; Garbade SF; Grünert SC; Kölker S
    Ann Clin Transl Neurol; 2024 Apr; 11(4):883-898. PubMed ID: 38263760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes.
    Bleeker JC; Kok IL; Ferdinandusse S; van der Pol WL; Cuppen I; Bosch AM; Langeveld M; Derks TGJ; Williams M; de Vries M; Mulder MF; Gozalbo ER; de Sain-van der Velden MGM; Rennings AJ; Schielen PJCI; Dekkers E; Houtkooper RH; Waterham HR; Pras-Raves ML; Wanders RJA; van Hasselt PM; Schoenmakers M; Wijburg FA; Visser G
    J Inherit Metab Dis; 2019 May; 42(3):414-423. PubMed ID: 30761551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
    Yamada K; Taketani T
    J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic characteristics and follow-up of patients with fatty acid β-oxidation disorders through expanded newborn screening in a Northern Chinese population.
    Wang S; Leng J; Diao C; Wang Y; Zheng R
    J Pediatr Endocrinol Metab; 2020 May; 33(6):683-690. PubMed ID: 32447334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of earlier versus later dietary management in long-chain 3-hydroxyacyl-CoA dehydrogenase or mitochondrial trifunctional protein deficiency: a systematic review.
    Fraser H; Geppert J; Johnson R; Johnson S; Connock M; Clarke A; Taylor-Phillips S; Stinton C
    Orphanet J Rare Dis; 2019 Nov; 14(1):258. PubMed ID: 31730477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening.
    Kang E; Kim YM; Kang M; Heo SH; Kim GH; Choi IH; Choi JH; Yoo HW; Lee BH
    BMC Pediatr; 2018 Mar; 18(1):103. PubMed ID: 29519241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic, biochemical, and clinical spectrum of patients with mitochondrial trifunctional protein deficiency identified after the introduction of newborn screening in the Netherlands.
    Schwantje M; Fuchs SA; de Boer L; Bosch AM; Cuppen I; Dekkers E; Derks TGJ; Ferdinandusse S; Ijlst L; Houtkooper RH; Maase R; van der Pol WL; de Vries MC; Verschoof-Puite RK; Wanders RJA; Williams M; Wijburg F; Visser G
    J Inherit Metab Dis; 2022 Jul; 45(4):804-818. PubMed ID: 35383965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The spectrum of peripheral neuropathy in disorders of the mitochondrial trifunctional protein.
    Grünert SC; Eckenweiler M; Haas D; Lindner M; Tsiakas K; Santer R; Tucci S; Spiekerkoetter U
    J Inherit Metab Dis; 2021 Jul; 44(4):893-902. PubMed ID: 33638202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial fatty acid profiles in a preterm infant with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
    Suganuma H; McPhee AJ; Bratkovic D; Gibson RA; Andersen CC
    Pediatr Int; 2019 Apr; 61(4):415-416. PubMed ID: 31025818
    [No Abstract]   [Full Text] [Related]  

  • 18. Early diagnosis and treatment by newborn screening (NBS) or family history is associated with improved visual outcomes for long-chain 3-hydroxyacylCoA dehydrogenase deficiency (LCHADD) chorioretinopathy.
    Gillingham MB; Choi D; Gregor A; Wongchaisuwat N; Black D; Scanga HL; Nischal KK; Sahel JA; Arnold G; Vockley J; Harding CO; Pennesi ME
    J Inherit Metab Dis; 2024 Jul; 47(4):746-756. PubMed ID: 38623632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-chain fatty acid oxidation during early human development.
    Oey NA; den Boer ME; Wijburg FA; Vekemans M; Augé J; Steiner C; Wanders RJ; Waterham HR; Ruiter JP; Attié-Bitach T
    Pediatr Res; 2005 Jun; 57(6):755-9. PubMed ID: 15845636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and biochemical outcome of patients with very long-chain acyl-CoA dehydrogenase deficiency.
    Rovelli V; Manzoni F; Viau K; Pasquali M; Longo N
    Mol Genet Metab; 2019 May; 127(1):64-73. PubMed ID: 31031081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.